Acutus Medical Stock News

NEW YORK, Feb. 26, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Acutus Medical, Inc. (NASDAQ: AFIB) between May 13, 2021 and November 11, 2021, inclusive (the “Class Period”) of the important April 18, 2022 lead plaintiff deadline .

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming April 18, 2022 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Acutus Medical, Inc. (“Acutus” or the “Company”) (NASDAQ: AFIB) common stock between May 13, 2021 and November 11, 2021, inclusive (the “Class Period”). Investors suffering losses on their Acutus investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal

NEW YORK, Feb. 24, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Acutus Medical, Inc. (NASDAQ: AFIB) between May 13, 2021 and November 11, 2021, inclusive (the "Class…

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Acutus Medical, Inc. (“Acutus” or the “Company”) (NASDAQ: AFIB) common stock between May 13, 2021 and November 11, 2021, inclusive (the “Class Period”). Acutus investors have until April 18, 2022 to file a lead plaintiff motion. If you suffered a loss on your Acutus i

NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Acutus Medical, Inc. (NASDAQ: AFIB) between May 13, 2021 and November 11, 2021, inclusive (the Class Period). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 18, 2022 .

Investor Action Alert: The Schall Law Firm Encourages Investors in Acutus Medical, Inc. with Losses of $100,000 to Contact the Firm

CARLSBAD, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arr

ATI Physical Therapy (ATIP) +16%. Cardiovascular Systems (CSII) +14%. Acutus Medical (AFIB) -9%. GeoVax Labs (GOVX) -9%.

CARLSBAD, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnose

There are some investors who buy U.S.-listed stocks that are trading below their liquidation values because they believe they can gain a lot from these stocks after the market has reappraised the shar

Nuveen Asset Management LLC increased its position in Acutus Medical, Inc. (NASDAQ:AFIB) by 13.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 44,369 shares of the companys stock after buying an additional 5,356 shares during the period. Nuveen Asset []

BTIG Research reaffirmed their buy rating on shares of Acutus Medical (NASDAQ:AFIB) in a research report sent to investors on Monday, TipRanks reports. BTIG Research currently has a $8.00 price target on the stock. AFIB has been the topic of several other reports. Zacks Investment Research downgraded shares of Acutus Medical from a hold rating [] The post Acutus Medicals (AFIB) Buy Rating Reaffirmed at BTIG Research appeared first on ETF Daily News .

During the last session, Acutus Medical Inc. (NASDAQ:AFIB)s traded shares were 0.4 million. At the end of the trading day, the stocks price was $3.44, reflecting an intraday gain of 3.61% or $0.12. The 52-week high for the AFIB share is $34.35, that puts it down -898.55 from that peak though still a striking 6.4% Could Acutus Medical Inc. (NASDAQ: AFIB) Regain All Of Its Losses Given A -21.85% Dip From High? Read More »

Acutus Medical, Inc. (NASDAQ:AFIB) has been given a consensus recommendation of Hold by the seven analysts that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating on the company. The average 12-month price target []

Zacks Investment Research lowered shares of Acutus Medical (NASDAQ:AFIB) from a hold rating to a sell rating in a research report sent to investors on Tuesday morning, Zacks.com reports. According to Zacks, Acutus Medical Inc. is an arrhythmia management company. It focused on the way cardiac arrhythmias are diagnosed and treated. Acutus Medical Inc. is []